BioMarin Pharmaceutical Inc BMRN Company Overview and Research Reports

BioMarin Pharmaceutical Inc, also known as BMRN, is a biotechnology company that focuses on developing treatments for rare genetic disorders.

Founded in 1997, BioMarin has grown to become a leader in the field of rare disease treatment, with a portfolio of products that address a range of conditions, including hemophilia A, Hunter syndrome, and Pompe disease.

Headquartered in San Rafael, California, BioMarin has a strong presence in the biotech industry, with a team of experienced scientists and researchers working tirelessly to develop new treatments and therapies.

BioMarin's commitment to innovation and patient care has earned the company numerous awards and recognition, including being named one of the "Best Places to Work" by the San Francisco Business Times.

BioMarin Pharmaceutical's financial performance is a key aspect of its overall health. The company's trailing total returns as of 10/24/2025 are a good indicator of its financial well-being.

BioMarin's profit margin is a notable 21.45%, which suggests that the company is able to maintain a healthy profit margin despite market fluctuations. This is a positive sign for investors.

The company's return on assets (ttm) is 7.50%, indicating that it is able to generate a decent amount of profit from its assets. This is a good sign for the company's financial health.

BioMarin's return on equity (ttm) is 11.62%, which is significantly higher than its return on assets. This suggests that the company is able to generate a higher profit from its equity.

Here's a quick rundown of BioMarin's key financial metrics:

BioMarin's revenue for the trailing 12 months is a substantial $3.06 billion, indicating a strong revenue stream.

BioMarin's recent performance has been impressive, with a strong Q2 earnings report that highlights its ability to scale revenue and margins.

The company's acquisition of Inozyme adds a high-conviction asset to its already robust pipeline, positioning it well for sustained outperformance.

BioMarin's focus on high-margin, high-need markets, combined with its financial discipline, makes it a compelling buy for long-term investors.

With key data expected in 2026 and regulatory approvals on the horizon, the stock is poised for a new era of growth.

BioMarin's strong balance sheet and expertise in rare diseases also mitigate risks, making it a rare combination of innovation, execution, and financial strength.

You might like: Johnson & Johnson - Merck Consumer Pharmaceuticals Company

BioMarin's business development strategy has been marked by strategic acquisitions, allowing the company to expand its portfolio and address unmet medical needs.

The company acquired Glyko Biomedical in 2002, marking its first major acquisition. This was followed by the acquisition of Huxley Pharmaceuticals in 2009, which brought with it the rights to amifampridine phosphate for the treatment of Lambert-Eaton myasthenic syndrome (LEMS).

BioMarin launched Firdapse in 2010, a product approved by the European Commission for the treatment of LEMS. The company continued to expand its portfolio with the acquisition of LEAD Therapeutics in 2010, gaining access to a PARP inhibitor for the treatment of rare cancers.

The company also acquired ZyStor Therapeutics in 2010, adding to its portfolio of treatments for lysosomal storage disorders. BioMarin's R&D efforts led to the announcement of a new program for vosoritide (BMN-111) in 2010, a peptide therapeutic for the treatment of achondroplasia.

In 2012, BioMarin acquired Zacharon Pharmaceuticals, a private biotechnology company focused on developing small molecules targeting pathways of glycan metabolism. The company continued to expand its portfolio with the acquisition of a histone deacetylase inhibitor chemical library from Repligen in 2014.

Worth a look: Acquisition of 21st Century Fox by Disney

BioMarin's largest acquisition to date was the purchase of Prosensa in 2014 for up to $840 million. Unfortunately, the company's treatments for Duchenne muscular dystrophy failed to attain FDA approval, and development ceased in 2016.

Here's a summary of BioMarin's major acquisitions:

The company's business development strategy has been instrumental in its growth and expansion into new therapeutic areas.

BioMarin has faced several controversies over the years, particularly regarding access to its experimental drugs and pricing of its products.

In 2010, the company's licensing of 3,4-DAP, marketed as Firdapse, led to a significant price increase, from $1,987 to $69,970. This has sparked debate about the company's prioritization of profits over patient needs.

BioMarin's stance on expanded access to its experimental drugs has also been criticized. In 2013, the company denied a patient with advanced ovarian cancer access to BMN 673, citing safety concerns. Similarly, in 2015, the company was accused of withholding a drug from a German child suffering from a brain disorder.

The company's actions have been criticized by patients, doctors, and regulatory bodies. For example, in 2019, patients who participated in a trial treatment for Kuvan were later denied access to the drug, prompting criticism from the NHS and Stephen Hammond MP.

In another case, a Belgian court ordered BioMarin to continue supplying Vimizim to a young girl suffering from Morquio syndrome free of charge, after the company stopped providing it due to failed negotiations with Belgian health authorities.

Here are some key dates related to BioMarin's controversies:

BioMarin's recent performance and strategic moves have positioned it as a standout in the biotech sector. The company's strong balance sheet and expertise in rare diseases make it a compelling investment opportunity.

The Inozyme acquisition adds a high-conviction asset to BioMarin's already robust pipeline. This move is expected to drive sustained outperformance as key data is expected in 2026 and regulatory approvals are on the horizon.

BioMarin's focus on high-margin, high-need markets, coupled with its financial discipline, makes it a solid choice for long-term investors. The company's ability to scale revenue and margins is a testament to its operational strength.

The biotech sector can be volatile, but BioMarin's strong fundamentals mitigate this risk. With a track record of commercializing complex therapies, the company is well-equipped to navigate the current market landscape.

BioMarin is not just navigating the current biotech landscape – it's shaping it. As the company moves closer to launching BMN 401 and other pipeline candidates, the stage is set for a new era of growth.

BioMarin Pharmaceutical has a strong focus on research and funding, particularly in the area of rare genetic disorders. They have a clear path to commercialization for their therapy INZ-701, which is a Phase 3 enzyme replacement therapy for ENPP1 Deficiency.

This condition affects an estimated 1,000-2,000 patients globally, many of whom face life-threatening complications in infancy. BioMarin is committed to addressing this unmet need through their acquisition of Inozyme.

BioMarin's core strength lies in developing enzyme therapies for genetically defined conditions, and INZ-701's subcutaneous delivery model and favorable safety profile position it as a first-in-class treatment with high pricing potential.

BioMarin Pharmaceutical Inc. has been consistently rated as a BUY by Argus, with a target price ranging from $58.000000 to $60.000000.

The investment ratings have been consistent over the past few weeks, with Argus providing updates every 4 days. The target price has been steadily increasing, with the highest price being $60.000000.

Here is a summary of the investment ratings:

The ratings are based on various subratings, including Industry, Management, Safety, Financial Strength, Growth, and Value.

Funding is a crucial aspect of research, and there are various ways to secure the necessary resources.

The National Institutes of Health (NIH) is a significant source of funding for research, providing over $32 billion in grants and contracts in 2020 alone.

Grants are a popular option for researchers, with the NIH receiving over 80,000 applications in 2020.

Private organizations and foundations also provide funding for research, such as the Bill and Melinda Gates Foundation, which has committed over $1 billion to global health initiatives.

Check this out: Lam Research

Crowdfunding is another way to secure funding, with platforms like Kickstarter and Indiegogo allowing researchers to raise money from a large number of people.

Government agencies and private organizations often provide matching funds, which can significantly increase the total amount of funding available.

In some cases, researchers may also be able to secure funding through partnerships with industry or academia.

If you're looking for similar companies to BioMarin Pharmaceutical, you can select up to 4 stocks to analyze using key performance metrics.

One stock that's often compared to BMRN is a company that offers similar products and services.

You can also compare BMRN to a company that has a similar market capitalization.

Another key metric to consider is revenue growth, which can give you an idea of a company's financial health.

BioMarin Pharmaceutical's own revenue growth has been impressive, with a certain percentage growth over a specific period.

You can also compare BMRN to a company that has a similar return on equity, which can indicate a company's profitability.